Physician profile
Stanley Warn
NPI 1912004391
$1,884.35
in general payments reported to CMS, 2019-2025
20 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $217 · 2021: $192 · 2022: $197 · 2023: $354 · 2024: $353 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $638.16 | 2019-2025 | Acuvue |
| Ocular Therapeutix, INC. | $146.48 | 2020 | |
| Horizon Therapeutics Plc | $139.03 | 2021-2023 | Tepezza |
| Coopervision INC. | $117.76 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $107.23 | 2021 | |
| Bausch & Lomb Americas INC. | $103.60 | 2022-2025 | Infuse, Alden Scleral Zenlens, Xiidra |
| Novartis Pharmaceuticals Corporation | $91.85 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $88.18 | 2019 | |
| Oyster Point Pharma, INC. | $82.32 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $61.93 | 2019-2025 | Cequa |
| Abbvie INC. | $57.54 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $50.65 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $47.79 | 2019 | |
| Alcon Vision LLC | $43.66 | 2024-2025 | Clareon, Precision7 |
| Dompe US, INC. | $24.12 | 2024 | Oxervate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.37 | 2025 | Iyuzeh |
| Visioneering Technologies, INC. | $18.35 | 2020 | |
| Allergan, INC. | $15.80 | 2019 | |
| Shire North American Group INC | $14.39 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Warn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.